Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT agai

Too many individuals with MS are not receiving access to the most effective care. Why? Whats behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan K

How burdensome is spasticity for patients with MS? Whats the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  These are the key questions Program Director Dr. Michael

In her Expert Commentary, Dr. Melanie Ward from West Virginia Universitys Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of

How aware are clinicians that MS should no longer be considered a White people only disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provi

Wheres the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? Join us as we discuss these and other questions with Dr. Michael Kornberg from the

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags warnings that something about the patients condition does not meet the accepted MS diagnostic criteria that need to be inv

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What

As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?  

COVID-19 vaccination. For many people with multiple sclerosis, its not a simple and straightforward process. The DMT theyre currently taking to control disease progression and moderate their symptoms particularly if its a beta cell- de